Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial. - Sáez-Llorens X; deAntonio R; López-Medina E; López P; Masuda T; Mendelman PM; Sherwood J; Baehner F; Borkowski A (Human vaccines & immunotherapeutics, 2025)